MedTrace Logo

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00006123 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2018-05-16

No results posted yet for this study

Summary

RATIONALE: Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy and peripheral stem cell transplantation followed by trastuzumab in treating women who have metastatic breast cancer.

Conditions

Interventions

BIOLOGICAL

trastuzumab

DRUG

carboplatin

DRUG

carmustine

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

thiotepa

PROCEDURE

peripheral blood stem cell transplantation

Sponsors & Collaborators

Principal Investigators

  • David Avigan, MD · Beth Israel Deaconess Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Primary Completion
2000-07-31
Completion
2000-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006123 on ClinicalTrials.gov